Cathepsin V ( CTSV ) Shapes the Epigenetic–Immune Landscape of Bladder Cancer and Emerges as a Noninvasive Biomarker
International Journal of Urology · 2026
DOI: 10.1111/iju.70609 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2026. Verfasst von Wallax Augusto Silva Ferreira und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cytogenomics and Environmental Mutagenesis, Environment Section (SEAMB), Evandro Chagas Institute (IEC), Ananindeua, PA, Brazil. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Evandro Chagas Institute (IEC/SVSA/MS-Brazil).
Abstract (Originalsprache)
Objective
The aim of this study was to perform a comprehensive characterization of CTSV regulation in bladder cancer (BC) and its association with clinicopathological features, prognosis, and tumor stroma modulation using multi‐omics databases.
Methods
We used integrative bioinformatics approaches with publicly available multi‐omics datasets. CTSV expression was evaluated across BC cohorts using TIMER2.0, GEPIA, GENT2, and GEO databases, while protein expression was examined with the Human Protein Atlas. Genomic alterations, DNA methylation, and histone modifications were analyzed using TCGA, UALCAN, ASD MethSurv, SMART, and DepMap databases. Associations with clinical outcomes, immune infiltration, and drug sensitivity were investigated through TCGA, CIBERSORT, TISIDB, single‐cell and spatial transcriptomics, and RNAactDrug platforms.
Results
We found that CTSV was upregulated in BC, especially in non‐papillary tumors. Moreover, its expression correlated positively with tumor grade, the presence of distant and lymph node metastases, resistance to therapy, and poorer overall and progression‐free survival. Furthermore, CTSV expression was associated with mutations in known BC driver genes ( TP53 , RB1 , and ERBB2 ) and showed a correlation with promoter hypomethylation, gene body methylation, and histone markers (e.g., H3K18ac1K23ac0), suggesting an epigenetic mechanism driving CTSV expression. The CTSV high and CTSV low groups exhibited a different stromal composition, with the former showing a more immunogenic signature. Finally, we found that cell lines and tumors highly expressing CTSV exhibit higher sensitivity to multiple chemotherapeutic drugs.
Conclusion
CTSV overexpression is associated with bladder cancer aggressiveness through epigenetic regulation and immune modulation, emerging as a promising prognostic biomarker and noninvasive diagnostic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Cytogenomics and Environmental Mutagenesis, Environment Section (SEAMB), Evandro Chagas Institute (IEC), Ananindeua, PA, Brazil.
- Department of Head and Neck Surgery, University of São Paulo Medical School, São Paulo, SP, Brazil.
- Center for Translational Research in Oncology, Cancer Institute of the State of São Paulo (ICESP), São Paulo, SP, Brazil.
- Laboratory of DNA Polymorphisms and Immunology, Department of Pathological Sciences, Biological Sciences Center, Londrina State University (UEL), Londrina, PR, Brazil.
- Department of Genetics and Morphology, Institute of Biological Sciences, University of Brasília (UnB), Brasília, DF, Brazil.
- Multiuser Cellular Biology and Ultrastructure Laboratory, Section of Hepatology, Evandro Chagas Institute (IEC), Belém, PA, Brazil.
ORCID-Profile: Wallax Augusto Silva Ferreira, Rolando André Rios Villacis
Förderung
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Evandro Chagas Institute (IEC/SVSA/MS-Brazil)
Zitieren
APA
Ferreira, W. A. S., Marchi, F. A., Vitiello, G. A. F., Villacis, R. A. R., Rodrigues, A. P. D., & Oliveira, E. H. C. (2026). Cathepsin V ( CTSV ) Shapes the Epigenetic–Immune Landscape of Bladder Cancer and Emerges as a Noninvasive Biomarker. International Journal of Urology. https://doi.org/10.1111/iju.70609
Vancouver
Ferreira WAS, Marchi FA, Vitiello GAF, Villacis RAR, Rodrigues APD, Oliveira EHC. Cathepsin V ( CTSV ) Shapes the Epigenetic–Immune Landscape of Bladder Cancer and Emerges as a Noninvasive Biomarker. International Journal of Urology. 2026. doi:10.1111/iju.70609
BibTeX
@article{Ferreira2026,
author = {Ferreira, Wallax Augusto Silva and Marchi, Fabio Albuquerque and Vitiello, Glauco Akelinghton Freire and Villacis, Rolando André Rios and Rodrigues, Ana Paula Drummond and Oliveira, Edivaldo Herculano Correa de},
title = {Cathepsin V ( CTSV ) Shapes the Epigenetic–Immune Landscape of Bladder Cancer and Emerges as a Noninvasive Biomarker},
journal = {International Journal of Urology},
year = {2026},
doi = {10.1111/iju.70609}
}
EUVIMED